- Home
- NIVF vs MYNZ Comparison
NIVF vs MYNZ Comparison
Compare NIVF & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- MYNZ
- Stock Information
- Founded
- NIVF 2011
- MYNZ 2021
- Country
- NIVF Thailand
- MYNZ Germany
- Employees
- NIVF N/A
- MYNZ N/A
- Industry
- NIVF
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- NIVF
- MYNZ Health Care
- Exchange
- NIVF NYSE
- MYNZ Nasdaq
- Market Cap
- NIVF 2.1M
- MYNZ 5.5M
- IPO Year
- NIVF N/A
- MYNZ 2021
- Fundamental
- Price
- NIVF $0.63
- MYNZ $1.80
- Analyst Decision
- NIVF
- MYNZ Buy
- Analyst Count
- NIVF 0
- MYNZ 2
- Target Price
- NIVF N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- NIVF 3.8M
- MYNZ 155.6K
- Earning Date
- NIVF 01-01-0001
- MYNZ 07-22-2025
- Dividend Yield
- NIVF N/A
- MYNZ N/A
- EPS Growth
- NIVF N/A
- MYNZ N/A
- EPS
- NIVF N/A
- MYNZ N/A
- Revenue
- NIVF $5,433,375.00
- MYNZ $893,991.00
- Revenue This Year
- NIVF N/A
- MYNZ $26.06
- Revenue Next Year
- NIVF N/A
- MYNZ $4.97
- P/E Ratio
- NIVF N/A
- MYNZ N/A
- Revenue Growth
- NIVF 5.79
- MYNZ N/A
- 52 Week Low
- NIVF $0.61
- MYNZ $1.34
- 52 Week High
- NIVF $656.00
- MYNZ $20.08
- Technical
- Relative Strength Index (RSI)
- NIVF 27.50
- MYNZ 57.87
- Support Level
- NIVF $0.61
- MYNZ $1.35
- Resistance Level
- NIVF $0.65
- MYNZ $2.15
- Average True Range (ATR)
- NIVF 0.12
- MYNZ 0.13
- MACD
- NIVF 0.03
- MYNZ 0.10
- Stochastic Oscillator
- NIVF 2.68
- MYNZ 71.67
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.